top of page
Abstract Background

Upcoming Webinars

_Les critères RECIST webinar (1).png

Join us for a practical, case-based webinar led by experts Dr. Maxime Rioux and Dr. Maxime Chénard-Poirier, designed to strengthen your knowledge and clinical skills in applying the RECIST criteria (Response Evaluation Criteria in Solid Tumors). This session addresses a significant practice gap in the consistent use of RECIST and aims to support better decision-making in oncology.

 

Learning objectives

By the end of this presentation, participants will be able to:

  • Familiarize yourself with the RECIST criteria.

  • Describe several examples of RECIST application in routine clinical practice.

 

This activity is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification (MOC) Program of the Royal College of Physicians and Surgeons of Canada, as well as a recognized professional development activity (Category A) as defined by the Collège des médecins du Québec. This activity has been approved by the Continuing Professional Development (CPD) Directorate of the Fédération des médecins spécialistes du Québec.

You may claim a maximum of 1.5 hours under Section 1 / recognized professional development activity (Category A). Participants should claim only the number of hours that corresponds to the duration of their participation.

IMG_6353.jpeg

Maxime Rioux

Radiologist

CHU de Québec

Conflict of interest 

Dr. Maxime Rioux is a diagnostic radiologist in the Department of Medicine at Université Laval, with specialized expertise in abdominal and pelvic imaging. He plays a key role in multidisciplinary oncology care by providing precise interpretation of imaging studies to support informed clinical decision-making.

Maxime Chénard-Poirier, MD, FRCPC

Medical Oncologist and Hematologist

CHU de Québec - Université Laval
Conflict of interest

Dr. Maxime Chénard-Poirier is a Clinical Professor in the Department of Medicine at the Faculty of Medicine, Université Laval, and an Associate Researcher in the Oncology Axis at the Hôtel-Dieu de Québec (HEJ) research centre

Scientific Committee

This content was developed by the RGOQ with an unrestricted grant from the following sponsor: Merck Canada. The sponsor had no role in the development of the content, the selection of topics, or the choice of speakers. The views expressed in this presentation are solely those of the authors/speakers: Dr. Maxime Rioux and Dr. Maxime Chénard-Poirier.

Abstract Background

Upcoming Webinars

Vincent Castonguay WEBINAR (6).png

Discover practical tips and cutting-edge information with Dr. Vincent Castonguay (Université Laval), as we explore how combining first-line chemotherapy and immunotherapy can transform outcomes for patients with recurrent or advanced endometrial cancer.

Learning objectives

By the end of this presentation, participants will be able to:

  • Evaluate the role of first-line chemotherapy combined with immunotherapy in the management of recurrent or advanced endometrial cancer, integrating current evidence and clinical trial results to guide therapeutic decisions.

  • Analyze the mechanisms of action and synergistic effects of immunotherapy when combined with chemotherapy, with a focus on their application in gynecologic oncology.

  • Apply updated protocols and guidelines for the treatment of recurrent or advanced endometrial cancer in clinical practice, taking into account patient-specific factors and multidisciplinary collaboration with pathologists and oncologists.

  • Discuss innovative approaches in gynecologic oncology, including the integration of molecular pathology and immunotherapy, to improve diagnostic and therapeutic strategies through interdisciplinary collaboration.

  • Identify potential challenges and adverse effects associated with combined chemotherapy and immunotherapy regimens, developing strategies to minimize risks and optimize outcomes for patients.

This activity is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification (MOC) Program of the Royal College of Physicians and Surgeons of Canada, as well as a recognized professional development activity (Category A) as defined by the Collège des médecins du Québec. This activity has been approved by the Continuing Professional Development (CPD) Directorate of the Fédération des médecins spécialistes du Québec.

You may claim a maximum of 1.5 hours under Section 1 / recognized professional development activity (Category A). Participants should claim only the number of hours that corresponds to the duration of their participation.

Vincent Castonguay_web.jpg

Vincent Castonguay

Hematologist-oncologist

CHU-de-Québec

Conflict of interest 

Vincent Castonguay has been a hematologist-oncologist at the CHU de Québec since 2012. He completed his residency in hematology and oncology at Université Laval, followed by a fellowship at the Princess Margaret Hospital in Toronto specializing in gynecologic malignancies and phase I clinical trials. His main clinical and research interests are in uro-oncology and gynecologic oncology. He served as Director of the Medical Oncology Program at Université Laval from 2014 to 2023 and is currently Co-Chief of the Hematology-Oncology Department at the CHU de Québec.

This content was developed by the RGOQ with an unrestricted grant from the following sponsor: Merck Canada. The sponsor had no role in the development of the content, the selection of topics, or the choice of speaker. The views expressed in this presentation are solely those of the author/speaker: Dr. Vincent Castonguay.

Scientific Committee

Webinar: Recurrent Ovarian Cancer

During this webinar, participants will review various cases, including typical and long-term trajectories of high-grade serous carcinoma, as well as cases of clear cell carcinoma and mucinous carcinoma, with an additional case focusing on low-grade serous carcinoma. Evaluate the implications of recurrent high-grade serous ovarian carcinoma based on the recurrence-free interval post-chemotherapy and analyze treatment options according to platinum sensitivity or resistance. Analyze the current evidence supporting therapeutic approaches for mucinous ovarian carcinoma. Identify and apply appropriate treatment strategies for patients with recurrent low-grade serous ovarian cancer.

Webinaire : Cancer de l’ovaire récidivant

Webinaire : Cancer de l’ovaire récidivant

Webinar on Obesity

20:00 - 20:10 Welcome Address & Learning Objectives Review obesity as a chronic disease. Discuss the stigma surrounding overweight and obesity. Neda Nasseri Pharmacist, Member of the Advisory Committee, Obesity Matters 20:10 - 20:30 Childhood Obesity Analyzing the relationship between childhood obesity and future risks of gynecologic cancer. Learning Objectives: Discuss childhood obesity and its underlying pathophysiology. Examine the importance of childhood obesity prevention and its impact on adult health, particularly cancer incidence. Review treatment goals and challenges for childhood obesity. Explain available therapeutic approaches. Julie St-Pierre Pediatrician, Maison de Santé Prévention 20:30 - 20:50 Impact of Obesity on Oncologic Treatments for Gynecologic Cancer Patients Evaluating the complexities and challenges of performing gynecologic oncology surgeries on patients with obesity. Learning Objectives: Examine pre-, intra-, and postoperative challenges associated with increased BMI. Identify strategies to improve the safety of surgical care for patients with high BMI. Discuss medical/systemic treatments and their adaptations for routine care in patients with obesity. Susie Lau – Gynecologic Oncologist, McGill University Health Centre Laurence Bernard – Gynecologic Oncologist, McGill University Health Centre 20:50 - 21:10 Medical Treatment in Adulthood Assessing the effectiveness of medical interventions for obesity and their implications for gynecologic oncology. Learning Objectives: Explore the link between obesity and gynecologic cancers. Define the role of obesity treatment in cancer survivorship and associated controversies. Provide an overview of obesity treatment options for patients in Canada. Marie-Hélène Auclair – Gynecologic Oncologist 21:10 - 21:35 Q&A Session

Obésité infantile

Obésité infantile
Obésité infantile
28:16

Obésité infantile

Webinaire sur l'obésité - vidéo complète
02:04:10

Webinaire sur l'obésité - vidéo complète

Impact de l'obésité sur les traitements oncologiques des patientes atteintes de cancers gynécologiques
22:01

Impact de l'obésité sur les traitements oncologiques des patientes atteintes de cancers gynécologiques

Obesity Matters
15:39

Obesity Matters

Webinaire_Obesite_Q&A
18:29

Webinaire_Obesite_Q&A

Traitement médical à l'âge adulte
18:45

Traitement médical à l'âge adulte

Impact de l'obésité sur les traitements oncologiques des patientes atteintes de cancers gynécologiques
12:21

Impact de l'obésité sur les traitements oncologiques des patientes atteintes de cancers gynécologiques

Rare Complications of Immunotherapy in Cancer Treatment

Join Our Upcoming Webinar! Designed specifically for healthcare professionals using immunotherapy to treat their patients, this session will explore the rare complications associated with these treatments and provide practical guidance through case studies and evidence-based practices. Learn to recognize and manage uncommon issues, identify molecules that mimic immune-related complications, and determine when urgent consultation is necessary. This essential training aims to enhance expertise in immunotherapy, ultimately leading to better patient outcomes. Learning Objectives: Familiarize yourself with rare complications of immunotherapy in gynecologic cancer treatment. Identify molecules that may mimic immune-oncology complications. Recognize urgent conditions requiring immediate consultation with a hematologist. Wednesday, June 5 | Online This activity is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification (MOC) Program of the Royal College of Physicians and Surgeons of Canada. It is also recognized as a professional development activity (Category A) by the Collège des médecins du Québec. You may claim up to 1.5 hours in Section 1 / recognized professional development activity (Category A). Participants should claim credit in accordance with the duration of their participation.

Introduction

Introduction
Introduction
28:15

Introduction

Webinaire sur l'immunotherapie - Cas 1
13:42

Webinaire sur l'immunotherapie - Cas 1

Webinaire sur l'immunotherapie - Cas 2
14:30

Webinaire sur l'immunotherapie - Cas 2

Webinaire sur l'immunotherapie - Cas 3
17:56

Webinaire sur l'immunotherapie - Cas 3

bottom of page